Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms
Taha, Karim; te Rijdt, Wouter P.; Verstraelen, Tom E.; Cramer, Maarten J.; de Boer, Rudolf A.; de Bruin-Bon, Rianne H.A.C.M.; Bouma, Berto J.; Asselbergs, Folkert W.; Wilde, Arthur A.M.; van den Berg, Maarten P.; Teske, Arco J.
(2021) JACC: Cardiovascular Imaging, volume 14, issue 5, pp. 885 - 896
(Article)
Abstract
OBJECTIVES: This study aimed to explore echocardiographic characteristics of phospholamban (PLN) p.Arg14del mutation carriers to investigate whether structural and/or functional abnormalities could be identified before onset of symptoms. BACKGROUND: Carriers of the genetic PLN p.Arg14del mutation may develop arrhythmogenic and/or dilated cardiomyopathy. Overt disease is preceded by a pre-symptomatic phase
... read more
of variable length in which disease expression seems to be absent. METHODS: PLN p.Arg14del mutation carriers with an available echocardiogram were included. Mutation carriers were classified as pre-symptomatic if they had no history of ventricular arrhythmias (VAs), a premature ventricular complex count of <500/24 h, and a left ventricular (LV) ejection fraction of ≥45%. In addition, we included 70 control subjects with similar age and sex distribution as the pre-symptomatic mutation carriers. Comprehensive echocardiographic analysis (including deformation imaging) was performed. RESULTS: The final study population consisted of 281 PLN p.Arg14del mutation carriers, 139 of whom were classified as pre-symptomatic. In comparison to control subjects, pre-symptomatic mutation carriers had lower global longitudinal strain and higher LV mechanical dispersion (both p < 0.001). In addition, post-systolic shortening (PSS) in the LV apex was observed in 43 pre-symptomatic mutation carriers (31%) and in none of the control subjects. During a median follow-up of 3.2 years (interquartile range: 2.1 to 5.6 years) in 104 pre-symptomatic mutation carriers, nonsustained VA occurred in 13 (13%). Presence of apical PSS was the strongest echocardiographic predictor of VA (multivariable hazards ratio: 5.11; 95% confidence interval [CI]: 1.37 to 19.08; p = 0.015), which resulted in a negative predictive value of 96% (95% CI: 89% to 98%) and a positive predictive value of 29% (95% CI: 21% to 40%). CONCLUSIONS: Global and regional LV mechanical alterations in PLN p.Arg14del mutation carriers precede arrhythmic symptoms and overt structural disease. Pre-symptomatic mutation carriers with normal deformation patterns in the apex are at low risk of developing VA within 3 years, whereas mutation carriers with apical PSS appear to be at higher risk.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: deformation imaging, early detection, echocardiography, family screening, phospholamban, risk stratification, Cardiology and Cardiovascular Medicine, Radiology Nuclear Medicine and imaging, Journal Article
ISSN: 1936-878X
Publisher: Elsevier Inc.
Note: Funding Information: This work was supported by the PLN Genetic Heart Disease Foundation, Netherlands Heart Institute, and the Dutch Heart Foundation (CVON2015-12 eDETECT and CVON2018-30 PREDICT2). Dr. te Rijdt is supported by the Dutch Heart Foundation (CVON PREDICT Young Talent Program) and the Leducq Foundation (CURE-PLaN Postdoctoral Fellowship). Prof. Dr. Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. Prof. Dr. de Boer has received speaker fees from Abbott, AstraZeneca, Novartis, and Roche. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2021 American College of Cardiology Foundation Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
(Peer reviewed)